Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Migraine drug may stop altitude sickness before it starts

NCT ID NCT07653516

First seen Jun 17, 2026 · Last updated Jun 18, 2026 · Updated 1 time

Summary

This study tests whether a single injection of fremanezumab, a drug used to prevent migraines, can stop acute mountain sickness (AMS) in healthy adults. Thirty volunteers will receive either the drug or a placebo one week before climbing to a high-altitude hut. Researchers will track symptoms like headache and nausea to see if the drug reduces AMS severity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MOUNTAIN SICKNESS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bern University Hospital

    Bern, 3010, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

acute mountain sickness altitude sickness migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.